UB Paderborn / Katalog / Suche / in CDI

P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B‐CELL LYMPHOMA (LBCL): EXTENDED FOLLOW‐UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY

HemaSphere, 2023-08, Vol.7 (S3), p.e458981a-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

The New England journal of medicine, 2022-12, Vol.387 (24), p.2220-2231

2022

Link zum Volltext

Verfügbarkeit prüfen

Risk of Cytokine Release Syndrome with Glofitamab Is Predicted By an Updated Model with a Potential Clinical Application

Blood, 2022-11, Vol.140 (Supplement 1), p.9493-9495

2022

Link zum Volltext

Verfügbarkeit prüfen

Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma

Blood, 2022-11, Vol.140 (Supplement 1), p.178-180

2022

Link zum Volltext

Verfügbarkeit prüfen

Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.7550-7550

2023

Link zum Volltext

Verfügbarkeit prüfen

Glofitamab step-up dosing (SUD): Complete response rates in updated efficacy data in heavily pretreated relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients (pts)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.7519-7519

2021

Link zum Volltext

Verfügbarkeit prüfen

Relapse Is Uncommon in Patients with Large B-Cell Lymphoma Who Are in Complete Remission at the End of Fixed-Course Glofitamab Treatment

Blood, 2022-11, Vol.140 (Supplement 1), p.1062-1064

2022

Link zum Volltext

Verfügbarkeit prüfen

Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: Pivotal phase II expansion results

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.7500-7500

2022

Link zum Volltext

Verfügbarkeit prüfen

Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma

Blood, 2020-11, Vol.136 (Supplement 1), p.46-48

2020

Link zum Volltext

Verfügbarkeit prüfen

Glofitamab Monotherapy Provides Durable Responses after Fixed-Length Dosing in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (pts)

Blood, 2021-11, Vol.138 (Supplement 1), p.2478-2478

2021

Link zum Volltext

Verfügbarkeit prüfen

MCL-467 Glofitamab Monotherapy Induces High Complete Response Rates in Patients With Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S462-S462

2023

Link zum Volltext

Verfügbarkeit prüfen

POSTER: MCL-467 Glofitamab Monotherapy Induces High Complete Response Rates in Patients With Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S212-S212

2023

Link zum Volltext

Verfügbarkeit prüfen

POSTER: ABCL-478 Glofitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and ≥2 Prior Therapies: Results From a Pivotal Phase II Expansion Study

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S206-S206

2023

Link zum Volltext

Verfügbarkeit prüfen

ABCL-478 Glofitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and ≥2 Prior Therapies: Results From a Pivotal Phase II Expansion Study

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S435-S435

2023

Link zum Volltext

Verfügbarkeit prüfen

Poster:ABCL-360 Glofitamab Step-Up Dosing (SUD): Updated Efficacy Data Show High Complete Response Rates in Heavily Pretreated Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (Pts)

Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S243-S243

2021

Link zum Volltext

Verfügbarkeit prüfen

ABCL-360: Glofitamab Step-Up Dosing (SUD): Updated Efficacy Data Show High Complete Response Rates in Heavily Pretreated Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (Pts)

Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S394-S394

2021

Link zum Volltext

Verfügbarkeit prüfen

Oral Abstract: ABCL-360: Glofitamab Step-Up Dosing (SUD): Updated Efficacy Data Show High Complete Response Rates in Heavily Pretreated Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (Pts)

Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S203-S203

2021

Link zum Volltext

Verfügbarkeit prüfen

HIV Stigmatizing Attitudes Among Men Accompanying Their Partners to Antenatal Care in Tanzania: A Mixed-Method Study

AIDS and behavior, 2021-10, Vol.25 (10), p.3172-3182

2021

Link zum Volltext

Verfügbarkeit prüfen

Short-term heat acclimation prior to a multi-day desert ultra-marathon improves physiological and psychological responses without compromising immune status

Journal of sports sciences, 2017-11, Vol.35 (22), p.2249-2256

2017

Link zum Volltext

Verfügbarkeit prüfen

Entry-Level Competencies Required of Primary Care Nurse Practitioners Providing HIV Specialty Care: A National Practice Validation Study

The Journal of the Association of Nurses in AIDS Care, 2016-05, Vol.27 (3), p.203

2016

Link zum Volltext

Verfügbarkeit prüfen

Similar Inflammatory Responses following Sprint Interval Training Performed in Hypoxia and Normoxia

Frontiers in physiology, 2016-08, Vol.7, p.332-332

2016

Link zum Volltext

Verfügbarkeit prüfen

The Development of an HIV Training Program for Nurse Practitioners

The Journal of the Association of Nurses in AIDS Care, 2016-05, Vol.27 (3), p.240

2016

Link zum Volltext

Verfügbarkeit prüfen

Slushflows: science and planning considerations for an expanding hazard

Natural hazards (Dordrecht), 2015-08, Vol.78 (1), p.333-354

2015

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B‐CELL LYMPHOMA (LBCL): EXTENDED FOLLOW‐UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Risk of Cytokine Release Syndrome with Glofitamab Is Predicted By an Updated Model with a Potential Clinical Application

Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma

Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy

Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study

Glofitamab step-up dosing (SUD): Complete response rates in updated efficacy data in heavily pretreated relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients (pts)

Relapse Is Uncommon in Patients with Large B-Cell Lymphoma Who Are in Complete Remission at the End of Fixed-Course Glofitamab Treatment

Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: Pivotal phase II expansion results

Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma

Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Glofitamab Monotherapy Provides Durable Responses after Fixed-Length Dosing in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (pts)

MCL-467 Glofitamab Monotherapy Induces High Complete Response Rates in Patients With Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma

POSTER: MCL-467 Glofitamab Monotherapy Induces High Complete Response Rates in Patients With Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma

POSTER: ABCL-478 Glofitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and ≥2 Prior Therapies: Results From a Pivotal Phase II Expansion Study

ABCL-478 Glofitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and ≥2 Prior Therapies: Results From a Pivotal Phase II Expansion Study

Poster:ABCL-360 Glofitamab Step-Up Dosing (SUD): Updated Efficacy Data Show High Complete Response Rates in Heavily Pretreated Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (Pts)

ABCL-360: Glofitamab Step-Up Dosing (SUD): Updated Efficacy Data Show High Complete Response Rates in Heavily Pretreated Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (Pts)

Oral Abstract: ABCL-360: Glofitamab Step-Up Dosing (SUD): Updated Efficacy Data Show High Complete Response Rates in Heavily Pretreated Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (Pts)

HIV Stigmatizing Attitudes Among Men Accompanying Their Partners to Antenatal Care in Tanzania: A Mixed-Method Study

Short-term heat acclimation prior to a multi-day desert ultra-marathon improves physiological and psychological responses without compromising immune status

Entry-Level Competencies Required of Primary Care Nurse Practitioners Providing HIV Specialty Care: A National Practice Validation Study

Similar Inflammatory Responses following Sprint Interval Training Performed in Hypoxia and Normoxia

The Development of an HIV Training Program for Nurse Practitioners

Slushflows: science and planning considerations for an expanding hazard

Suchergebnisse filtern